A pharmacist by training, Dr. Nicolas Bertrand is an assistant professor at Laval University’s School of Pharmaceutical Studies. He is also a researcher in the department of Endocrinology and Nephrology at the CHU de Quebec Research Center. His research in nanomedicine focuses on potentiating the efficacy of therapeutic molecules by using nanotechnologies. He is the editor of the European Journal of Pharmaceutics and Biopharmaceutics (Elsevier, IF: 4.2) and director of the « Biopharmacy et pharmacometrics » strategic cluster of the Réseau Québécois de Recherche sur les Médicaments (rqrm.ca). He is an associate member of the Institute on Nutraceuticals and Functional Foods (INAF) and of the Centre de Recherche sur les Matériaux Avancés (CERMA).

Encapsulating bioactive molecules through differentiated technologies

Many drugs in development, or already on the market, possess suboptimal physiochemical or pharmacological characteristics. Nanomedicine can harness the unique features of nanomaterials to facilitate the administration of these drugs, or potentiate their efficacy. Encapsulation of bioactive molecules in nanoparticles can prevent their metabolism, ameliorate their pharmacokinetics, or ensure their optimal distribution to diseased tissues. Altogether, these effects can pave the way for more efficient and better tolerated drugs.

Dr. Nicolas Bertrand’s laboratory uses functional polymers and lipids to encapsulate a variety of bioactive molecules in clinically-relevant drug delivery vehicles.

Elucidate the interactions of nanomaterials with the immune system

Like other drugs, the use of nanoparticles as drug delivery vehicles can trigger unexpected or undesirable reactions. The type of system, its size, or the materials used in its preparation can all influence the nature and extent of its interactions with the immune system. The development of better tolerated nanomedicines necessitates a better understanding of how drug delivery platforms interact with the various components of the immune system.

Through a unique expertise in the preparation of nanoparticle libraries, combined with an established knowledge in preclinical pharmacokinetics, Dr. Nicolas Bertrand’s laboratory specialises in studying the fate of nano- and biomaterials in living animals. This approach leads to an integrated understanding of the interactions of materials with complete, functional biological systems.

2705, boulevard Laurier
Québec, Québec
Canada G1V 4G2
46 entries « 5 of 5 »

Bertrand N, Simard P, Leroux JC

Serum-stable, long-circulating, pH-sensitive PEGylated liposomes

Journal Article

Methods Mol Biol, 605 , 2010.

Abstract | Links:

Bertrand N, Bouvet C, Moreau P, Leroux JC

Transmembrane pH-gradient liposomes to treat cardiovascular drug intoxication

Journal Article

ACS Nano, 4 (12), 2010.

Abstract | Links:

Bertrand N, Fleischer JG, Wasan KM, Leroux JC

Pharmacokinetics and biodistribution of N-isopropylacrylamide copolymers for the design of pH-sensitive liposomes

Journal Article

Biomaterials, 30 (13), 2009.

Abstract | Links:

Bertrand N, Leclair G, Hildgen P

Modeling drug release from bioerodible microspheres using a cellular automaton

Journal Article

Int J Pharm, 343 (1-2), 2007.

Abstract | Links:

Elsabahy M, Perron ME, Bertrand N, Yu GE, Leroux JC

Solubilization of docetaxel in poly(ethylene oxide)-block-poly(butylene/styrene oxide) micelles

Journal Article

Biomacromolecules, 8 (7), 2007.

Abstract | Links:

Rabanel JM, Bertrand N, Sant S, Louati S, Hildgen P

Polysaccharides hydrogels for the preparation of immunoisolated cell delivery systems

Book Chapter

Marchessault RH, Ravenelle F, Zhu XX (Ed.): Polysaccharides for drug delivery and pharmaceutical applications, pp. 305-339, Washington, DC, American Chemical Society, 2006, ISBN: 9780841239609.

46 entries « 5 of 5 »
Signaler des ajouts ou des modifications

Active projects

  • Anti-PEG antibodies and adverse reactions to PEGylated drugs: effect of mRNA vaccination and novel mitigation strategies., from 2022-09-01 to 2024-08-31
  • Causes and consequences of anti-PEG antibodies, from 2023-10-01 to 2028-09-30
  • Development, optimization and evaluation of novel nanoparticle formulations for extra-hepatic targeted gene therapy, from 2022-12-05 to 2024-12-04
  • Have mRNA vaccines changed the biopharmacy of drugs? A pilot correlative study on the links between vaccination with mRNA vaccines and the incidence of acute infusion reactions in women with breast and ovarian cancer treated with, from 2023-04-01 to 2025-03-31
  • Infrastructure de développement de nanomédecines pour le traitement des maladies du foie cholestatiques et autoimmunes, from 2023-05-01 to 2024-08-27
  • Methods to study the long-term effects of nanoparticles in vivo, from 2023-04-01 to 2028-03-31
  • Nanomatériaux pour cibler le microbiote intestinal et altérer le métabolisme des acides biliaires, from 2023-04-01 to 2026-03-31
  • Nanopharmacologie et nanosciences pharmaceutiques : une approche multidisciplinaire pour des nanomédecines plus efficaces et mieux tolérées, from 2022-07-01 to 2026-06-30
  • NanoQB : réseau Québec-Brésil pour la recherche collaborative en nanotechnologie pharmaceutique, from 2023-07-21 to 2025-06-30
  • Pharmacological optimization of OpKemo, a silica-based nanoparticle platform for oncology, from 2022-01-31 to 2024-08-30

Recently finished projects

  • Adaptation de la méthode SERP (size exclusion of radioactive polymers) aux nanovecteurs de silice , from 2021-12-17 to 2024-03-31
  • Causes and consequences of anti-PEG antibodies, from 2023-03-01 to 2024-02-29
  • Development of siRNA-based nanomedicines for the treatment of cholestatic autoimmune liver diseases, from 2022-09-21 to 2023-03-31
  • Elucidating the link between toxicities of PEG-asparaginase and antiPEG antibodies, from 2021-04-01 to 2022-07-31
  • Engineering functional nanoparticles using libraries of polymers, from 2016-04-01 to 2023-03-31
  • FGR - Projet MAKISU ; de l'impression 3D au médicament injectable, from 2022-02-15 to 2023-02-14
  • Nanopharmacologie et nanomédecine : vers le développement de plates-formes technologiques pour la vectorisation des médicaments, from 2018-07-01 to 2022-06-30
  • Nanopharmacologie et nanomédecine: vers le développement de plates-formes technologiques pour la vectorisation des médicaments, from 2018-07-01 to 2022-06-30
  • Plate-forme de production de nanoparticules lipidiques pour le développement de thérapies à base d'acides nucléiques, from 2022-03-22 to 2023-09-28
  • Targeting extracellular hydroxyapatite to deliver nucleic acids to surrounding cells, from 2022-09-21 to 2023-03-31
  • Un nano-vaccin contre les maladies cardiovasculaires, from 2020-04-01 to 2024-03-31
  • Use of nanoparticles to understand and treat vascular calcification in chronic kidney disease, from 2020-10-01 to 2023-05-31
Data provided by the Université Laval research projects registery